Back to Search Start Over

Helical tomotherapy for post-mastectomy radiation therapy with or without breast implant: a single institution experience.

Authors :
Dejean R
Chaltiel L
Izar F
Chira C
Leray H
Jouve E
Simon L
Massabeau C
Source :
Clinical and translational radiation oncology [Clin Transl Radiat Oncol] 2022 May 04; Vol. 35, pp. 37-43. Date of Electronic Publication: 2022 May 04 (Print Publication: 2022).
Publication Year :
2022

Abstract

Introduction: We report on our experience of using Helical Tomotherapy (HT) in the context of post-mastectomy radiation therapy (PMRT) with or without immediate implant-based breast Reconstruction (IBR).<br />Material and Methods: The study included a total of 173 patients who underwent PMRT with HT between 2013 and 2015 in our institution (87 immediate breast reconstructions with retropectoral implants (IBR + ), 86 without reconstructions (IBR-)). The chest wall target volume included subcutaneous tissue and pectoralis muscle and excluded the posterior region of the implant as well as the ribs.<br />Results: Median time to initiation of the first adjuvant treatment from mastectomy was similar between the two groups (p = 0.134). Dose coverage to the chest wall was significantly improved for the IBR + group (V95% = 95.1 % versus 92.0 %; p < 0.0001). The irradiated volume of the ipsilateral lung was significantly decreased in the IBR + group with a median V20Gy of 11.6 %, compared to 15.2 % for the control group (p < 0.0001). The median heart V15Gy was also significantly lower in the IBR + group than in the control group (1.7 vs 2.5 %; p = 0.0280). The reconstruction failure rate was 14.9% (n = 13). After a median follow-up of 65 months, loco regional recurrence rate was low in both groups: 3 patients (3.4%) in the IBR + group and 5 patients (5.8%) in the control group, without any local recurrence in the posterior part of the implant.<br />Conclusions: The presence of a breast implant reduces cardiac and pulmonary doses during Tomotherapy irradiation, without compromising oncological outcomes.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2022 The Author(s).)

Details

Language :
English
ISSN :
2405-6308
Volume :
35
Database :
MEDLINE
Journal :
Clinical and translational radiation oncology
Publication Type :
Academic Journal
Accession number :
35591849
Full Text :
https://doi.org/10.1016/j.ctro.2022.04.012